A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis

被引：1
|
作者：
DeAngelo, D. J.
Tefferi, A.
Mesa, R. A.
Paley, C. S.
Wadleigh, M.
Snyder, D.
Ondovik, M. S.
Rine, J.
Bhalla, K. N.
机构：
[1] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin Rochester, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
    DeAngelo, Daniel J.
    Mesa, Ruben A.
    Fiskus, Warren
    Tefferi, Ayalew
    Paley, Carole
    Wadleigh, Martha
    Ritchie, Ellen K.
    Snyder, David S.
    Begna, Kebede
    Ganguly, Siddhartha
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (03) : 326 - 335
  • [12] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
    Vannucchi, A. M.
    Heidel, F. H.
    Ribrag, V.
    Kiladjian, J. J.
    Passamonti, F.
    Hayat, A.
    Conneally, E.
    Kindler, T.
    Martino, B.
    Lipka, D. B.
    Acharyya, S.
    Gopalakrishna, P.
    Loechner, S.
    Mu, S.
    Harrison, C. N.
    HAEMATOLOGICA, 2014, 99 : 129 - 130
  • [13] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    A Tefferi
    L Saeed
    C A Hanson
    R P Ketterling
    A Pardanani
    N Gangat
    Leukemia, 2017, 31 : 2851 - 2852
  • [14] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Newberry, Kate J.
    Manshouri, Taghi
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
  • [15] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    Tefferi, A.
    Saeed, L.
    Hanson, C. A.
    Ketterling, R. P.
    Pardanani, A.
    Gangat, N.
    LEUKEMIA, 2017, 31 (12) : 2851 - 2852
  • [16] PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF
    Pemmaraju, N.
    Kantarjian, H.
    Cortes, J.
    Kadia, T.
    DiNardo, C.
    Estrov, Z.
    Pierce, S.
    Zhou, L.
    Salinas, K.
    Tuttle, C.
    Mak, P. Y.
    Carter, B. Z.
    Verstovsek, S.
    HAEMATOLOGICA, 2016, 101 : 95 - 95
  • [17] Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Bose, Prithviraj
    Pierce, Sherry
    Zhou, Lingsha
    Estrov, Zeev
    Tuttle, Carla Kay
    Salinas, Karina
    Mak, Po Yee
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [18] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [19] Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis?
    Masarova, Lucia
    Daver, Naval
    Pemmaraju, Naveen
    Bose, Prithviraj
    Pierce, Sherry
    Manshouri, Taghi
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2015, 126 (23)
  • [20] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis
    Alexandre Guy
    Audrey Bidet
    Catherine Ling
    Charline Caumont
    Lisa Boureau
    Jean-François Viallard
    Marie Parrens
    Virchows Archiv, 2021, 479 : 755 - 764
12345